AG-270 - Moligand™,10mM in DMSO , CAS No.2201056-66-6

CAS: 2201056-66-6 Cat. No.: A655557 分子式: C30H27N5O2 分子量: 489.57 PubChem CID: 134307820
注文可能
グレード&純度 Moligand™ ? Moligand™ — Aladdin's line of ligands and bioactive small molecules. Use for receptor, pathway, and binding studies needing defined small-molecule tools. 10mM in DMSO
Storage
Store at -80°C
Shipped In
Dry ice packs + Cold packs
★
サイズ
USA
ドイツ (EU)*
価格
個数
1ml
A655557-1ml
受注生産 · 8~12週間
$659.90
Enter a quantity for the sizes you want to add.

概要

AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC 50 of 14 nM

In Vitro

AG-270 demonstrates potent reduction in levels of intracellular SAM , as well as MTAP-–selective antiproliferative activity in the HCT116 MTAP isogenic cell model in vitro. AG-270 exhibits an IC 50 of 20 nM in HCT116 MTAP- cell SAM at 72 h. MAT2A is a key enzyme in the methionine salvage pathway, responsible for generating the universal methyl donor, S-adenosylmethionine (SAM). MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AG-270 shows excellent microsomal, hepatocyte, and in vivo metabolic stability across species (human, mouse, rat, dog, and monkey). AG-270 exhibits T1/2 values of 5.9 h, 4.2 h, 4.8 h and 21.3 h in mouse, rat, monkey and dog, respectively . AG-270 (200 mg/kg, orally, q.d. for 38 days) results in dose-dependent reduction in tumor SAM levels and tumor growth of KP4 MTAP- xenografts and is well tolerated, with mean body weight loss <5% . Combining AG-270 with taxanes and gemcitabine yielded additive-tosynergistic antitumor activity, with the docetaxel combination yielding 50% complete tumor regressions in select models; combination benefits are observed in PDX models derived from esophageal, NSCLC, and pancreatic cancers. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Pancreatic KP4 MTAP - xenograft mouse model . Dosage: 10-200 mg/kg. Administration: Orally, q.d. for 38 days. Result: Led to dose-dependent reductions in tumor SAM levels and tumor growth of KP4 MTAP- xenografts (TGI = 36% (10 mg/kg), 48% (30 mg/kg), 66% (100 mg/kg), 67% (200 mg/kg).

IC50& Target:IC50: 14 nM (MAT2A)

仕様

仕様と純度
Moligand™, 10mM in DMSO
生化学的・生理学的メカニズム
AG-270 is an allosteric, noncompetitive, first-in-class, reversible and orally active MAT2A inhibitor, with an IC 50 of 14 nM.
保管条件
Store at -80°C
入荷
Dry ice packs + Cold packs
この製品は冷冷この冷このこの製品の運送が必要です。地上およびその他の経済サービスは利用できません。
等級
Moligand™
名前と識別子
異性体SMILES
COC1=CC=C(C=C1)C2=C(N=C3C(=C(NN3C2=O)C4=CC=CC=C4)C5=CCCCC5)NC6=CC=CC=N6
代替CAS番号
2201056-66-6
PubChem CID
134307820
分子量
489.57

詳細データ

証明書(CoA、COO、BSE/TSEと分析図)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:

Find and download the COA for your product by matching the lot number on the packaging.

1 results found

Lot NumberCertificate Type日付商品
J2610916J2610916Certificate of AnalysisOct 15, 2026 A655557
よくある質問と記事
ソリューション計算機
レビュー

顧客レビュー

グレードの選択でお困りですか?

当社のグレード選定ガイドでは、カタログ内のすべてのバリエーションについて、純度、安定剤の状態、用途への適合性を網羅しています。

Moligand™ グレードガイドを見る →

Shall we send you a message when we have discounts available?

Remind me later

Thank you! Please check your email inbox to confirm.

Oops! Notifications are disabled.